Delivery Order SPE2DB20D2014-SPE2DB25FB33E

Award Date 3/13/25
Potential Completion Date 3/14/25
Potential Value $1.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,570.42 contract is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medical product, to support federal healthcare programs. The contract has an ultimate completion date of January 24, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,122.67 contract is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, with a period of performance through February 19, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,569.84, is for the supply of XYOSTED 50 MG/0.5 ML AUTO-INJ 0.5ML, a medical product, to support military healthcare programs. The contract is a Firm Fixed Price arrangement with a planned completion date of January 5, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,012.14, is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML medical products. The order has an ultimate completion date of January 6, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,724.30, is for the provision of XYOSTED 50 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has an ultimate completion date of March 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The award has a ceiling value of $1,246.80 and a performance period through March 20, 2024. The contract is for the provision of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, in support of military treatment...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,986.05, is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. The contract has a Firm Fixed Price pricing type and a completion date of May 9, 2023. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) valued at...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,050.12 firm fixed-price delivery order is for the XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medical supply item. The contract has an ultimate completion date of November 15, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,785.40, is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has a completion date of December 31, 2024 and is a Firm Fixed Price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $1,987.91, is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product. The contract has an ultimate completion date of January 31, 2025 and is a Firm Fixed Price Delivery Order. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB25FB33E
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,896.65, is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, with a period of performance through March 14, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/12/25, 9:45 AM